go-v.orgdoi

Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer

Cynthia Liu, Malek Shatila, Antony Mathew, Antonio Pizuorno Machado, Austin R. Thomas, Hao Chi Zhang, Anusha Shirwaikar Thomas, David M. Faleck, Pauline Funchain, Jessica R. Philpott, Petros D. Grivas, Michel Obéid, Franck Carbonnel, Yinghong Wang · Journal of Cancer · 2023

  • DOI 10.7150/jca.84261
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2023

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2023

Abstract

Background: Immune-mediated diarrhea and colitis (IMDC) frequently develop after treatment with immune checkpoint inhibitors.C-reactive protein (CRP) is a serum inflammatory biomarker used to stratify and monitor disease severity in many inflammatory conditions.However, CRP level is not specific and is widely influenced by various factors non-specific to bowel inflammation.We aimed to study the utility of CRP as a predictor of disease severity and therapy response in IMDC.Methods: We performed a retrospective analysis of patients diagnosed with IMDC who had CRP measured at IMDC onset and after treatment with selective immunosuppressive therapy (SIT: infliximab and vedolizumab), between 01/2016 and 02/2022 at MD Anderson Cancer Center.Patient demographics, clinical characteristics, and IMDC data were collected and analyzed.Results: Our sample of 128 patients had a median age of 67 years; most were white (89.8%); and male (65.6%).Prior to development of IMDC, 15 (11.7%) were initially treated with anti-CTLA-4, 42 (32.8%)with anti-PD-1 or PD-L1, and 71 (55.5%) with a combination of both.We found higher CRP level was associated with higher CTCAE grade of clinical symptoms such as diarrhea (p=0.015),colitis (p=0.013), and endoscopic findings (p=0.016).While CRP levels decreased after IMDC treatment, there was no significant association between CRP levels with clinical remission, endoscopic remission or histologic remission.There also was no significant correlation between CRP level and recurrence of IMDC, or with fecal calprotectin levels.Conclusion: CRP level may be useful to assess initial severity of IMDC, including grade of diarrhea and colitis and degree of endoscopic inflammation.However, CRP is not a robust surrogate biomarker for assessing treatment response or disease recurrence.Despite the reduction of CRP levels observed following IMDC treatment, this finding might be nonspecific and potentially confounded by concurrent clinical factors, such as underlying malignancy, other inflammatory processes, and systemic anti-cancer therapy.Further studies of the role of CRP are warranted in patients with cancer and IMDC.

Open the resolved locator · 10.7150/jca.84261

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:17 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v14p1913.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.